Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2383-2391

  Debono, Miguel ^a,c   Prema, Anna ^a   Hughes, Timothy J B ^a   Bull, Matthew ^b   Ross, Richard J ^a,c   Newell Price, John ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL RADIOGRAPHY; ADRENAL INCIDENTALOMA; ADRENALECTOMY; AGED; ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTRAABDOMINAL FAT; LIPID ANALYSIS; LIPID STORAGE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DETERMINATION; SUBCUTANEOUS FAT;

ADRENAL GLAND NEOPLASMS; AGED; CROSS-SECTIONAL STUDIES; CUSHING SYNDROME; DEXAMETHASONE; FEMALE; HUMANS; HYDROCORTISONE; INTRA-ABDOMINAL FAT; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84878522518     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4276     Document Type: Article

References (41)

1. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25:309-340. (Pubitemid 38528713)
2. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:601-610.
3. Tauchmanova L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87:4872-4878. (Pubitemid 35316318)
4. Terzolo M, Pia A, Ali A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87:998-1003. (Pubitemid 36121054)
5. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617. (Pubitemid 43674231)
6. Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011;96:1223-1236.
7. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164:851-870.
8. Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11β-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res. 2004;59:359-393.
9. Pedersen SB, Jonler M, Richelsen B. Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab. 1994;78:1354-1359. (Pubitemid 24181004)
10. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring). 2006;14:336-341. (Pubitemid 46214766)
11. Nicklas BJ, Penninx BW, Cesari M, et al. Association of visceral adipose tissue with incident myocardial infarction in older men and women: the Health, Aging and Body Composition Study. Am J Epidemiol. 2004;160:741-749. (Pubitemid 39362211)
12. Rockall AG, Sohaib SA, Evans D, et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol. 2003;149:561-567. (Pubitemid 38054701)
13. Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol. 2012;166:669-677.
14. Morelli V, Masserini B, Salcuni AS, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf). 73:161-166.
15. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540. (Pubitemid 351656485)
16. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344-349. (Pubitemid 351289042)
17. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998;19:647-672. (Pubitemid 28467716)
18. NIH Consensus Statement. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements. 2002;19:1-25.
19. Kuk JL, Church TS, Blair SN, Ross R. Does measurement site for visceral and abdominal subcutaneous adipose tissue alter associations with the metabolic syndrome? Diabetes Care. 2006;29:679-684. (Pubitemid 44115373)
20. Vatanparast H, Chilibeck PD, Cornish SM, et al. DXA-derived abdominal fat mass, waist circumference, and blood lipids in postmenopausal women. Obesity (Silver Spring). 2009;17:1635-1640.
21. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism. 1987;36:54-59. (Pubitemid 17016386)
22. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology. 1999;211:283-286. (Pubitemid 29161765)
23. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697-738. (Pubitemid 32113289)
24. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem. 1983;21:709-720. (Pubitemid 14208512)
25. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care. 2000;23:465-471. (Pubitemid 30185788)
26. Hayashi T, Boyko EJ, Leonetti DL, et al. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004;140:992-1000.
27. Olsen H, Nordenstrom E, Bergenfelz A, Nyman U, Valdemarsson S, Palmqvist E. Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine. 2012;42:164-173.
28. Huizenga NA, Koper JW, de Lange P, et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab. 1998;83:47-54. (Pubitemid 28498309)
29. Reimondo G, Allasino B, Bovio S, et al. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas. J Endocrinol Invest. 2011;34:e1-5.
30. Enzi G, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr. 1986;44:739-746. (Pubitemid 17208993)
31. Pasquali R, Ambrosi B, Armanini D, et al. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab. 2002;87:166-175. (Pubitemid 34084687)
32. Veilleux A, Rheaume C, Daris M, Luu-The V, Tchernof A. Omental adipose tissue type 1 11β-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab. 2009;94:3550-3557.
33. Cooper MS, Blumsohn A, Goddard PE, et al. 11β-Hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab. 2003;88:3874-3877. (Pubitemid 37034541)
34. Morelli V, Donadio F, Eller-Vainicher C, et al. Role of glucocorticoid receptor polymorphism in adrenal incidentalomas. Eur J Clin Invest. 2010;40:803-811.
35. Giordano R, Marzotti S, Berardelli R, et al. BClI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison's disease. Clin Endocrinol (Oxf). 2012;77:863-870.
36. Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 95:2736-2745.
37. van Schoor NM, Dennison E, Lips P, Uitterlinden AG, Cooper C. Serum fasting cortisol in relation to bone, and the role of genetic variations in the glucocorticoid receptor. Clin Endocrinol (Oxf). 2007;67:871-878. (Pubitemid 350135130)
38. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009;249:388-391.
39. Bjorntorp P, Rosmond R. Obesity and cortisol. Nutrition. 2000;16:924-936.
40. Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93:1553-1562. (Pubitemid 351656487)
41. Stewart PM. Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab. 2010;95:2618-2620.